NF-kappaB activating scaffold proteins as signaling molecules and putative therapeutic targets.
Activation of transcription factors such as NF-kappa B occurs through signaling pathways involving sequential phosphorylation of a variety of substrates by distinct kinases. Proper assemby and activation of these kinases require interaction with non-enzymatic and essential partners named scaffold proteins. Here, we describe how the NF-kappa B activating scaffold proteins involved in the signaling pathways triggered by the pro-inflammatory cytokines TNF alpha, IL-1 beta and by the CD40 ligand play such roles. We also illustrate the human genetic diseases that are linked to mutations affecting genes coding for these proteins. We suggest that these scaffold proteins may be specifically targeted by novel therapeutical agents for the treatment of inflammation or cancers.
Chariot
Alain
A
Laboratory of Medical Chemistry and Human Genetics, Center for Cellular and Molecular Therapy, Pathology, CHU Sart-Tilman, 4000 Liège, Belgium. Alain.chariot@ulg.ac.be
Meuwis
Marie-Alice
MA
Bonif
Marianne
M
Leonardi
Antonio
A
Merville
Marie-Paule
MP
Gielen
Jacques
J
Piette
Jacques
J
Siebenlist
Ulrich
U
Bours
Vincent
V
D019013:CD40 Antigens / Q000378:metabolism; D006801:Humans; D007375:Interleukin-1 / Q000378:metabolism; D016328:NF-kappa B / Q000187:drug effects / Q000502:physiology*; D011499:Protein Processing, Post-Translational; D015398:Signal Transduction; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism
D019013:CD40 Antigens; D007375:Interleukin-1; D016328:NF-kappa B; D014409:Tumor Necrosis Factor-alpha